Melanotan I
- Category
- Skin & Cosmetic
- Administration routes
- Injectable
- Regulatory status
- FDA-approved
A linear alpha-MSH analog that binds MC1R to raise eumelanin, sold as an approved implant and also used, outside its approval, for cosmetic tanning. Evidence for EPP photoprotection is solid; quality-of-life and vitiligo gains are moderate; other claims are speculative. Skin darkening is expected, and nausea affected 19% in the FDA trial safety population. Moles need monitoring, and unregulated products carry melanoma case reports. Approved only for EPP; cosmetic tanning relies on unregulated products sold online.
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.
Overview
Scenesse (afamelanotide / Melanotan I) is a synthetic 13-amino-acid peptide that stimulates your skin to produce protective dark melanin (eumelanin) without UV exposure. Developed at the University of Arizona in the 1980s, it is FDA-approved (October 2019) as Scenesse for erythropoietic protoporphyria (EPP), a rare genetic condition causing extreme sun sensitivity and painful skin reactions to light. Unlike Melanotan II, which activates multiple melanocortin receptors and causes sexual and appetite side effects, Melanotan I selectively targets the MC1R receptor responsible for tanning.
How it works in the body
A linear analog of alpha-MSH that binds to MC1R receptors on melanocytes in the skin. This activates adenylyl cyclase, increasing cAMP levels, which drives the production of eumelanin (protective dark pigment). The result is skin darkening that provides some UV protection.
Research overview
Afamelanotide works by binding to the MC1R receptor on skin cells, shifting melanin production from the reddish, potentially damaging type (pheomelanin) to the brown, protective type (eumelanin). This also triggers antioxidant activity, DNA repair mechanisms, and anti-inflammatory signaling. Studies show it reduces sunburn cells by 50% and significantly decreases UV-induced DNA damage. It is delivered as a slow-release implant under the skin, with most of the drug released within 2 days and fully cleared by day 10. Beyond EPP, research has explored its potential for vitiligo, solar urticaria, and photoprotection in organ transplant patients, though these remain off-label uses.
Who researches Melanotan I?
Commonly researched by
People researching inflammation management
Studied for anti-inflammatory effects across various conditions.
People researching photoprotection in epp
One of the primary studied benefits of Melanotan I.
Important considerations for
Those who are pregnant or breastfeeding
AbsoluteNo human reproductive safety data exists for this peptide. Effects on fetal development are unknown.
Anyone under 18
AbsoluteNo pediatric safety data. Not recommended for use in minors.
Those with Known hypersensitivity
AbsoluteDiscontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).
Safety & interactions
General cautions
Pregnancy or breastfeeding
AbsoluteNo human reproductive safety data exists for this peptide. Effects on fetal development are unknown.
Children under 18
AbsoluteNo pediatric safety data. Not recommended for use in minors.
Known hypersensitivity
AbsoluteDiscontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).
How to read the ratings
- Benefits
- = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
- Risks
- = level of concern: High · Moderate · Low · Theoretical
- Interactions
- = direction with this peptide: Protective / Synergistic · Caution · Neutral
Risk summary(9)
Rated by level of concern
Nausea and headache (very common, >10% of patients)
ModerateFDA SCENESSE (afamelanotide) prescribing information, Adverse Reactions table
Implant site reactions including bruising and discomfort
HighFDA SCENESSE prescribing information (Adverse Reactions; Dosage and Administration)
Darkening of existing moles — requires regular dermatologic monitoring for melanocytic changes
HighFDA SCENESSE prescribing information, Warnings and Precautions (Skin Monitoring)
Diffuse skin hyperpigmentation experienced by nearly all patients
HighFDA SCENESSE prescribing information; PMID 33683075 ('nearly all patients experience diffuse hyperpigmentation')
Rare serious hypersensitivity reactions including anaphylaxis (post-marketing reports)
ModeratePost-marketing hypersensitivity reports; FDA/EU SCENESSE safety labeling
New melanocytic nevi may develop during treatment
LowFDA SCENESSE prescribing information, Adverse Reactions table
Unregulated melanotan products: 4 case reports of melanoma emergence, unknown purity/dosing, melanocytic changes in moles and dysplastic nevi
ModeratePMID 28266027 (Habbema et al., Int J Dermatol 2017, including the explicit 'conclusive evidence... is lacking' caveat); PMID 28905366 (Adler et al., Australas J Dermatol 2017)
Safety not established in children, pregnancy/breastfeeding, or patients with liver/kidney impairment
ModerateFDA SCENESSE prescribing information, Use in Specific Populations; PMID 33683075
Long-term effects of repeated eumelanin stimulation beyond clinical trial durations not fully characterized
TheoreticalPMID 28063031 (Clin Pharmacokinet 2017, 25-year safety observation); PMID 33683075
Interaction summary(8)
Rated by direction with this peptide
Narrowband UV-B phototherapy
SynergisticModerateCombining afamelanotide implants with NB-UVB produced greater and faster repigmentation in vitiligo than NB-UVB alone (48.6% vs 33.3% at day 168) in a randomized multicenter trial, replicated in a randomized trial in Asian patients. The pivotal trial was open-label, and the combination darkens uninvolved skin, increasing contrast in darker phototypes.
PMID 25230094 (JAMA Dermatol 2015, open-label RCT); PMID 31987791 (J Am Acad Dermatol 2020)
Sun-protective measures (sunscreen, clothing, UV avoidance)
ProtectiveLowAfamelanotide is an adjunct, not a replacement: induced tanning provides only partial UV protection, and patients should maintain standard photoprotection and continue routine skin surveillance during therapy.
FDA SCENESSE prescribing information (Skin Monitoring); PMID 28266027
Intentional UV exposure / tanning beds
CautionLowBehavioral rather than pharmacologic: cosmetic darkening can create a false sense of protection and encourage additional UV exposure, a concern raised in reviews of unregulated melanotan use within tanning culture. No clinical study has quantified the resulting risk.
PMID 28266027 (Habbema et al., Int J Dermatol 2017)
Other melanocortin analogues (melanotan-II, bremelanotide, unregulated tanning peptides)
CautionModerateUsing more than one MC1R agonist adds no established benefit while compounding pigmentary, gastrointestinal and melanocytic-lesion effects, and illicit products carry unknown purity and dosing; melanotan-II is less selective (MC3R/MC4R activity) and has case-report associations with nausea, flushing and priapism. Evidence is case-report/review level, not comparative trial data.
PMID 28266027; PMID 28905366
Anticoagulants and antiplatelet agents (warfarin, DOACs, aspirin, clopidogrel)
CautionTheoreticalThere is no pharmacologic interaction and no interaction data. The label identifies implant site reaction generally — not bruising or hematoma specifically — as the most common adverse event. The practical point is procedural: the implant is inserted subcutaneously, so insertion technique and bleeding risk deserve attention in anticoagulated patients.
FDA SCENESSE prescribing information (Dosage and Administration; Adverse Reactions) — extrapolation, no interaction studies performed
Systemic immunosuppressants / organ transplant recipients
CautionTheoreticalIn patients already at elevated skin-cancer risk, drug-induced hyperpigmentation may obscure clinical detection of melanocytic lesions; no interaction or outcome data exist in this population, and dermatologic surveillance should be intensified.
Mechanism plus FDA SCENESSE skin-monitoring warning (no clinical interaction studies performed)
CYP450-metabolized drugs (general co-medication)
NeutralLowAfamelanotide is a 13-amino-acid peptide cleared by peptidase hydrolysis with no CYP-mediated metabolism, and no formal drug-drug interaction studies are described in the label; clinically meaningful pharmacokinetic interactions are not expected.
PMID 28063031 (Clin Pharmacokinet 2017 PK/PD review); FDA SCENESSE prescribing information
Photosensitizing drugs (tetracyclines, thiazides, amiodarone, voriconazole, NSAIDs)
CautionTheoreticalNo studied interaction, but drug-induced photosensitivity can offset the partial photoprotection afamelanotide provides in EPP and other photodermatoses; review medication lists before attributing breakthrough phototoxicity to treatment failure.
Mechanism-based; no interaction data in FDA SCENESSE labeling
Known risks(9)
Nausea and headache (very common, >10% of patients)
Implant site reactions including bruising and discomfort
Darkening of existing moles — requires regular dermatologic monitoring for melanocytic changes
Diffuse skin hyperpigmentation experienced by nearly all patients
Rare serious hypersensitivity reactions including anaphylaxis (post-marketing reports)
New melanocytic nevi may develop during treatment
Unregulated melanotan products: 4 case reports of melanoma emergence, unknown purity/dosing, melanocytic changes in moles and dysplastic nevi
Safety not established in children, pregnancy/breastfeeding, or patients with liver/kidney impairment
Long-term effects of repeated eumelanin stimulation beyond clinical trial durations not fully characterized
Drug interactions(4)
Anticoagulants / blood thinners
Patients on blood thinning medication may experience increased bruising or bleeding at implant insertion site due to subcutaneous administration method.
Photosensitizing medications
Drugs causing photosensitivity (tetracyclines, fluoroquinolones, NSAIDs, thiazides) may have altered effects when combined with afamelanotide-induced melanin changes. No formal interaction studies conducted.
Other melanocortin receptor agonists
Using it with melanotan II or other MC receptor agonists could cause excessive melanocortin receptor stimulation; avoid concurrent use.
Hepatically/renally cleared drugs
Metabolism and distribution of afamelanotide not fully characterized as of 2017. Caution in patients with liver or kidney impairment; contraindicated in those populations.
Research & benefits
Evidence base
- Evidence Level
- Level 1 — FDA Approved
- Total Studies
- 20
- Human Studies
- 10
Two pivotal Phase III multicenter, randomized, double-blind, placebo-controlled trials (168 patients total: 74 EU, 94 US). Additional Phase II/III trials in vitiligo, polymorphic light eruption, and other photodermatoses. FDA approval based on 3 trials totaling 244 adults across 22 US and European sites. Post-marketing observational data from 200-patient German cohort confirms long-term safety.
Researched for(8)
Rated by confidence in the evidence
Photoprotection in EPP
HighTwo blinded, placebo-controlled trials enrolled 168 patients: 74 in the EU and 94 in the US.
PMID 26132941 (Langendonk et al., N Engl J Med 2015;373:48-59); FDA SCENESSE prescribing information
Eumelanin production without UV
HighSkin darkening was recorded as a trial-confirmed effect in vehicle-controlled human studies, without UV exposure.
FDA SCENESSE prescribing information (Adverse Reactions); PMID 28063031 (Minder et al., Clin Pharmacokinet 2017 PK/PD review)
Quality of life improvement in EPP
MediumQuality-of-life gains were a secondary endpoint in RCTs, with further support from a retrospective cohort study.
PMID 26132941 (secondary endpoint); PMID 36244556 (J Am Acad Dermatol 2023, retrospective cohort)
DNA repair enhancement
SpeculativeDNA-repair responses have been investigated in a small human mechanistic study; sponsor-reported biopsy findings remain preliminary.
PMID 28063031 (review states afamelanotide 'enhances DNA repair processes'); in vitro melanocyte literature
Anti-inflammatory photoprotection
LowAnti-inflammatory effects are established in cell and animal studies, but not isolated in human trials.
PMID 28063031; PMID 33683075 (Wu & Cotliar, J Drugs Dermatol 2021)
Potential vitiligo treatment
MediumOpen-label randomized trials with NB-UVB showed modest repigmentation gains over UVB alone, unblinded and off-label.
PMID 25230094 (Lim et al., JAMA Dermatol 2015;151:42-50, open-label RCT); PMID 31987791 (J Am Acad Dermatol 2020, vitiligo in Asians)
Polymorphic light eruption prevention
LowA review cites RCT evidence for this use, but no primary trial report could be verified.
PMID 33683075 (J Drugs Dermatol 2021, cites but does not reproduce RCT evidence for PLE); PMID 28063031 (lists PLE among clinical applications)
Broad photodermatosis applications
LowSmall pilot trials suggest possible benefit for polymorphic light eruption and solar urticaria.
PMID 30517779 (McNeil et al., Skin Therapy Lett 2018); PMID 33683075 (J Drugs Dermatol 2021) reviews of afamelanotide, which is Melanotan I itself (same molecule, [Nle4,D-Phe7]-alpha-MSH), not a separate related compound
Benefits(8)
Photoprotection in EPP
Eumelanin production without UV
Quality of life improvement in EPP
DNA repair enhancement
Anti-inflammatory photoprotection
Potential vitiligo treatment
Polymorphic light eruption prevention
Broad photodermatosis applications
Key studies(6)
Afamelanotide for Erythropoietic Protoporphyria
Phase III RCT (double-blind, placebo-controlled)168 patients (74 EU + 94 US)6 months in the US trial; 9 months in the EU trialLangendonk JG, Balwani M, Anderson KE, et al.
New England Journal of Medicine
2015
Afamelanotide was associated with increased duration of sun exposure without pain and improved quality of life in EPP patients. Well tolerated with no drug-related serious adverse events.
German Cohort Observational Study to Investigate the Short- and Long-Term Safety and Clinical Effectiveness of Afamelanotide 16 mg (SCENESSE) in Patients With EPP
Post-authorization safety study (observational)200 patientsOngoing registryHomey B, Schelonke K, Schlegel CM, et al.
Photodermatology, Photoimmunology & Photomedicine
2025
Long-term safety profile consistent with clinical trials. Significant QoL improvement (p < 0.0001). 91% treatment continuation rate. Safe across age groups including patients over 70.
Wensink D, Wagenmakers MAEM, Langendonk JG
Expert Review of Clinical Pharmacology
2021
First effective approved treatment for EPP. Clinical effectiveness appears greater in practice than trial data suggested. Current dosing intervals may be insufficient for some patients. Common adverse events: headache, fatigue, nausea.
Afamelanotide for Treatment of the Protoporphyrias: Impact on Quality of Life and Laboratory Parameters in a US Cohort
Retrospective cohort study29 patients (26 received ≥2 implants)VariableLeaf RK, Naik H, Jiang PY, et al.
Life (Basel)
2024
Median time to symptom onset increased from 12.5 to 120 minutes after treatment. Significant QoL improvements and reduced depression. No improvement in protoporphyrin levels, indicating benefits operate through photoprotective mechanisms rather than reducing porphyrin accumulation.
Wu J, Cotliar R
Journal of Drugs in Dermatology
2021
Beyond EPP, afamelanotide shows promise in vitiligo (RCT data), polymorphic light eruption, acne vulgaris, Hailey-Hailey disease, and solar urticaria. Dual photoprotective and anti-inflammatory properties. No serious adverse effects reported.
Habbema L, Halk AB, Neumann M, Bergman W
International Journal of Dermatology
2017
Unregulated melanotan products pose risks including melanocytic changes in moles and newly emerging dysplastic nevi. Four case reports of melanomas emerging during/after melanotan use. Afamelanotide is the only thoroughly tested and approved α-MSH analog.
What research suggests over time
Weeks 2-4
FDA-approved (Scenesse)Afamelanotide exposure occurs over days after implantation; the pigmentation effect lasts longer than measurable plasma exposure.
Months 2-3
Phase 3 RCTDramatic reduction in EPP photosensitivity reactions; significant increase in pain-free sun exposure duration vs placebo (NEJM 2015).
Long-term
Phase 3 + LTFUSustained protection with quarterly implants; 91% treatment continuation rate; significant QoL improvement (p<0.0001) in long-term safety follow-up (Photodermatology 2025).
Prescribing labels
FDA-Approved Labels
This page does not list doses. Each product below has an FDA label with its prescribing information.
- Protocol
- Scenesse (afamelanotide)
- Notes
- Dosing is set by your prescriber and the FDA label.
- Source
- FDA label on DailyMed
Monitoring & labs
Baseline before starting, then per marker schedule during protocol.
Baseline labs(4)
Complete Blood Count (CBC)
Optimal All markers within mid-rangeEstablishes baseline for detecting hematological changes.
Lab normal Standard reference ranges
Comprehensive Metabolic Panel (CMP)
Optimal Liver enzymes <25, glucose 75–90, eGFR >90Liver and kidney function baseline.
Lab normal Standard reference ranges
C-Reactive Protein (CRP)
Optimal Under 1.0 mg/LBaseline inflammatory marker relevant to skin conditions.
Lab normal Under 3.0 mg/L
Dermatologic screening (mole mapping)
Baseline skin assessment — melanocyte-stimulating peptide with documented melanoma concern.
Ongoing tracking(3)
Liver enzymes (ALT/AST)
Every 8 weeksOptimal ALT & AST under 25 U/LHepatic monitoring for injectable protocols.
Lab normal ALT 7–56, AST 10–40 U/L
CRP
Every 8 weeksOptimal Under 1.0 mg/LTrack inflammatory skin markers.
Lab normal Under 3.0 mg/L
Dermatologic check
Every 12 weeksMonitor for new or changing moles — melanocyte-stimulating peptide.
Retest schedule(5)
Baseline
critical
Before starting
Full baseline panel — establish reference values for all monitored markers.
Early follow-up
critical
Week 4-6
Spot-check for early changes — focus on glucose, liver enzymes, and any peptide-specific markers.
Mid-protocol
critical
Week 12
Comprehensive retest. Compare all markers to baseline.
Ongoing
standard
Quarterly
Continued monitoring during extended protocols.
Post-protocol
standard
4-6 weeks after stopping
Confirm return to baseline. Important for GH and metabolic peptides.
When to stop and reassess(4)
ALT or AST
stopAbove 2× upper limit of normal (>~80 U/L)
Stop protocol and consult a provider — possible drug-induced liver injury.
eGFR
stopDrop of >15 mL/min/1.73m² from baseline, or below 60
Stop protocol and consult a provider — possible kidney function decline.
Symptoms
stopNew severe symptoms correlating with lab changes
Stop protocol and seek medical evaluation immediately.
Skin lesions
stopAny new or changing mole
Stop protocol and consult a dermatologist — melanocyte-stimulating peptide.
Lab monitoring helps track your body's response to Melanotan I. Any unexplained changes should prompt discussion with your prescribing provider.
Regulation & availability
Why researchers look at it
Clinical studies showed a 50% reduction in sunburn cells and significant decrease in UV-induced DNA damage, with treated patients going from tolerating 12 minutes of sunlight to 2 hours pain-free. Trials in vitiligo and photoprotection for transplant patients at elevated skin cancer risk could expand it well beyond its current rare-disease approval.
- Estimated cost
- $2,000-5,000/treatment (Scenesse implant); limited availability
- FDA status
- FDA-approved (October 8, 2019). Brand name: Scenesse. NDA 210797. Designated first-in-class medication. Orphan drug designation: US July 17, 2008; EU May 8, 2008. Approved indication: increasing pain-free light exposure in adult patients with erythropoietic protoporphyria (EPP). Approval based on three clinical trials with 244 adults across 22 sites. No FDA REMS was required. EMA approved December 2014. Italy provided reimbursed early access under Law 648/1996 from May 2010.
- WADA status
- Afamelanotide is not named on the WADA 2026 Prohibited List and has approval for human therapeutic use. S0 is determined by substance approval, not whether a prescription is for an approved indication. A mandatory TUE requirement for Scenesse has not been established; athletes should obtain a product-specific determination from their anti-doping organization. Melanotan II is a different substance.
- Prescribability
- FDA-approved prescription drug (Scenesse) for EPP, given as a subcutaneous implant by healthcare professionals only. Available through specialty pharmacies and certified treatment centers. Unregulated 'melanotan' products sold online are not the same as the approved pharmaceutical product.
- Availability
- FDA-approved as Scenesse (subcutaneous implant) since October 2019. EMA-approved since December 2014. Australian TGA approved October 2020. Available only through certified healthcare providers and specialty pharmacies for diagnosed EPP patients. Must be administered by a healthcare professional. Expiration of orphan exclusivity on October 8, 2026 does not establish a generic launch date; patent and approval requirements also matter. Unregulated 'melanotan' products are widely sold online but are not equivalent to the approved pharmaceutical product and carry significant safety risks.
International status
EU
EMA-approved (Scenesse) for EPP
US
FDA-approved (Scenesse) for EPP only
Australia
TGA-approved (Scenesse)
Regulatory timeline(10)
- 1980sSynthesis at University of ArizonaAfamelanotide synthesized as one of several potent α-MSH analogs by researchers at the University of Arizona.
- 2004Depot formulation developedSubcutaneous implant formulation enabling controlled slow-release delivery developed.
- 2006Epitan renamed to Clinuvel PharmaceuticalsDevelopment company rebranded as Clinuvel Pharmaceuticals Ltd.
- 2007Health agency warnings beginMultiple national health organizations begin issuing safety warnings about unregulated melanotan products.
- 2010-05Italian early access (AIFA)Italian reimbursed early access: AIFA provides access to afamelanotide for EPP under Law 648/1996.
- 2008Orphan drug designation (US and EU)Orphan drug designation for EPP: EU May 8, 2008; US July 17, 2008.
- 2014-12EMA approval (EU)European Medicines Agency grants marketing authorization for Scenesse for EPP in adults.
- 2019-10-08FDA approval (US)FDA approves Scenesse (NDA 210797) for increasing pain-free light exposure in adult EPP patients. Designated first-in-class. Based on 3 trials with 244 adults.
- 2020-10TGA approval (Australia)Australian Therapeutic Goods Administration approves afamelanotide for EPP.
- 2026-10-08Orphan exclusivity expiresThis date alone does not establish generic approval eligibility or market entry; patent requirements also apply.
Sources & FAQs
Research sources(9)
- Afamelanotide for Erythropoietic Protoporphyria (NEJM)
- German Cohort Observational Study — Afamelanotide Long-Term Safety
- Afamelanotide for prevention of phototoxicity in EPP (Expert Review)
- Afamelanotide Treatment in US Cohort — QoL and Lab Parameters
- Afamelanotide: Orphan Drug with Broad Dermatologic Applications
- Risks of Unregulated Use of α-MSH Analogues
- Afamelanotide — Wikipedia
- Afamelanotide — DermNet NZ
- FDA Prescribing Information — Scenesse
Frequently asked questions(6)
What is the difference between Melanotan I and Melanotan II?
Melanotan I (afamelanotide) is a linear 13-amino-acid peptide selective for the MC1R receptor, FDA-approved as Scenesse for EPP. Melanotan II is a shorter cyclic 7-amino-acid peptide that acts on multiple melanocortin receptors (MC1R, MC3R, MC4R, MC5R), causing tanning plus sexual arousal, appetite suppression, and other effects. Melanotan II is NOT approved by any regulatory agency and carries greater side effect risks.
Is Melanotan I FDA-approved?
Yes. Afamelanotide (Scenesse) was FDA-approved on October 8, 2019, for increasing pain-free light exposure in adult patients with erythropoietic protoporphyria (EPP). It is designated as a first-in-class medication. It received EU marketing authorization on December 22, 2014, and Australian approval on October 26, 2020, followed by registration on November 18, 2020.
Can I use Melanotan I just for tanning?
The FDA-approved product (Scenesse) is only prescribed for EPP. Multiple national health agencies have issued warnings against this practice.
How is Scenesse administered?
Scenesse is a biodegradable implant (about 1.7 cm long) inserted subcutaneously near the hip by a healthcare professional, timed before periods of expected sun exposure. Dosing is set by your prescriber and the FDA label.
Does Melanotan I cause melanoma?
In clinical trials and post-marketing surveillance of the approved product (Scenesse), no evidence links afamelanotide to increased melanoma risk. However, unregulated melanotan products have been associated with 4 case reports of melanomas emerging from existing moles. Afamelanotide darkens existing moles, making dermatologic monitoring important.
What are the most common side effects?
Very common (>10%): nausea and headache. Common (1-10%): implant site reactions, back pain, upper respiratory infections, darkening of existing moles (melanocytic nevi), fatigue, dizziness, and mild skin changes. Most side effects resolve within 72 hours. Rare cases of hypersensitivity including anaphylaxis reported post-marketing.